Portage Biotech Added to Russell 2000(R) Index
Westport, Connecticut--(Newsfile Corp. - June 29, 2021) - Portage Biotech Inc., (NASDAQ: PRTG) ("Portage" or the "Company") a clinical-stage immuno-oncology company focused on the development of therapies targeting cancer treatment resistance, today announced that the Company has been added to the Russell 2000 Index at the conclusion of the 2021 Russell Indexes annual reconstitution, effective after the U.S. market opened on June 28. "Inclusion in the Russell 2000 index marks another key...
2021-06-29 9:00 AM EDT
Portage Biotech Inc. Announces Pricing of Public Offering of 1,000,000 Ordinary Shares
Westport, Connecticut--(Newsfile Corp. - June 24, 2021) - Portage Biotech Inc. (NASDAQ: PRTG) ("Portage" or the "Company") a clinical-stage immuno-oncology company focused on the development of therapies and treatments targeting cancer treatment resistance, today announced that it has priced its previously announced underwritten public offering of 1,000,000 ordinary shares. The public offering price of each ordinary share is $23.00. In addition, Portage has granted the underwriters a 30-day...
2021-06-24 9:00 AM EDT
Portage Biotech Inc. Announces Proposed Offering of Ordinary Shares
Westport, Connecticut--(Newsfile Corp. - June 23, 2021) - Portage Biotech Inc. (NASDAQ: PRTG) ("Portage" or the "Company") a clinical-stage immuno-oncology company focused on the development of therapies and treatments targeting cancer treatment resistance, today announced that it has commenced an underwritten public offering of its ordinary shares. In addition, Portage expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of the ordinary shares...
2021-06-23 4:10 PM EDT
Portage Biotech Highlights Safety and Survival Data from Intensity Therapeutics' IT-01 Study of INT230-6 (PORT-1) at ASCO 2021 Annual Meeting
- Data from the IT-01 trial demonstrate the safety of INT230-6 (PORT-1) as both a monotherapy and in combination with checkpoint inhibitors in solid tumors - Survival data looks favorable compared to similar historical populations, balanced for prognostic factorsWestport, Connecticut--(Newsfile Corp. - June 2, 2021) - Portage Biotech Inc., (NASDAQ: PRTG) ("Portage" or the "Company") a clinical-stage immuno-oncology company focused on the...
2021-06-02 8:30 AM EDT
Portage Biotech Announces Voluntary Delisting from the Canadian Securities Exchange
Westport, Connecticut--(Newsfile Corp. - April 16, 2021) - Portage Biotech Inc., (NASDAQ: PRTG) (CSE: PBT.U) ("Portage" or the "Company") a clinical-stage immuno-oncology company focused on the development of therapies targeting cancer treatment resistance, today announced that it plans to voluntarily delist its common shares ("Shares") from the Canadian Securities Exchange (the "CSE"). Since Portage's Shares began trading on the NASDAQ Capital Market ("Nasdaq") in February 2021, the majority...
2021-04-16 9:00 AM EDT
Portage Biotech Highlights First Patient Dosed in PRECIOUS-01 Study of PORT-3 for the Treatment of NY-ESO-1 Positive Solid Tumors
Novel platform allows co-targeting of iNKT cells and tumor antigens in a single product- Trial marks the first milestone in a comprehensive clinical development plan to evaluate iNKT agonists to improve outcomes in a variety of solid tumors Westport, Connecticut--(Newsfile Corp. - April 8, 2021) - Portage Biotech Inc. (NASDAQ: PRTG) (CSE: PBT.U) ("Portage" or the "Company"), a clinical-stage immuno-oncology...
2021-04-08 9:00 AM EDT
Portage Biotech Highlights Initiation of the Invincible Trial, a Phase 2 Early Stage Breast Cancer Study from Intensity Therapeutics
- The INVINCIBLE trial is a phase 2 study with a primary endpoint one month after starting treatment - Eight other phase 2 clinical data reads are expected from INT230-6 (PORT-1) over the next 24 monthsWestport, Connecticut--(Newsfile Corp. - March 25, 2021) - Portage Biotech Inc. (NASDAQ: PRTG) (CSE: PBT.U) ("Portage" or the "Company") a clinical stage immuno-oncology company accelerating research and development to overcome immune resistance, today highlights that Intensity Therapeutics...
2021-03-25 9:00 AM EDT
Portage Biotech Divests Portage Pharmaceuticals Limited to Juvenescence Ltd
Toronto, Ontario--(Newsfile Corp. - March 4, 2021) - Portage Biotech Inc. (NASDAQ: PRTG) (CSE: PBT.U) ("Portage" or the "Company") a clinical stage immuno-oncology company accelerating research and development to overcome immune resistance, today announced the divestment of its three legacy businesses; Portage Pharmaceuticals Limited (PPL), including subsidiaries Portage Glasgow Ltd. and EyGen Ltd, to Juvenescence...
2021-03-04 8:00 AM EST
Portage Announces Filing of Third Quarter Financial Statements
Toronto, Ontario--(Newsfile Corp. - March 2, 2021) - Portage Biotech Inc. (NASDAQ: PRTG) (CSE: PBT.U) ("Portage" or the "Company") a clinical stage immune-oncology company accelerating research and development to overcome immune resistance, today announced the filing of its interim financial statements and related management's analysis and discussion for the period ended December 31, 2020 (the third quarterly filings.) These documents are available from SEDAR, the SEC, and the company's...
2021-03-02 8:00 AM EST
Portage Commences Trading on Nasdaq
Toronto, Ontario--(Newsfile Corp. - February 25, 2021) - Portage Biotech Inc. (CSE: PBT.U) (NASDAQ: PRTG) ("Portage" or the "Company") a clinical stage immuno-oncology company accelerating research and development to overcome immune resistance, today announced the commencement of trading of its ordinary shares on the NASDAQ Capital Market ("Nasdaq") under the symbol "PRTG." The Company's ordinary shares will continue to trade on the Canadian Securities Exchange (CSE).As one of the largest...
2021-02-25 8:00 AM EST
Portage Biotech Provides Research and Development Update and Announces NASDAQ Listing Approval
Company to advance three clinical-stage programs in pipeline ---- Portage has received approval and is preparing for NASDAQ listing --Toronto, Ontario--(Newsfile Corp. - February 11, 2021) - Portage Biotech Inc. (CSE: PBT.U) (OTC Pink: PTGEF) ("Portage" or the "Company") today announced its 2021 research and development goals, including advancing three of its pipeline assets through clinical trials during the upcoming year. Portage also announced that it has received approval from the NASDAQ...
2021-02-11 8:00 AM EST
Portage Announces Filing of Q1 Interim Financial Statements; Correction to SalvaRX Loan Note Settlement Announcement
Toronto, Ontario--(Newsfile Corp. - October 16, 2020) - Portage Biotech Inc. (CSE: PBT.U) (OTC Pink: PTGEF) ("Portage" or the "Company") announces that the Company has filed its interim financial statements and related management's discussion and analysis for the three-month period ending June 30, 2020 and related delivery requirements (the "Q1 Filings").Previously on August 28, 2020, Portage announced that pursuant to blanket relief granted by the Canadian Securities Administrators, it would...
2020-10-16 4:01 PM EDT
Portage Issues Common Shares and Warrants in Settlement of SalvaRx Loan Note Obligations
Toronto, Ontario--(Newsfile Corp. - October 13, 2020) - Portage Biotech Inc. (CSE: PBT.U) (OTC Pink: PTGEF) ("Portage" or the "Company") wishes to announce that it has issued 375,014 common shares at a deemed price of US$6.64 per common share and 72,291 common share purchase warrants exercisable at a price of $6.64 per common share for a period of 2 years (collectively, the "Settlement Securities") to settle approximately US$4.4 million of certain debt obligations and equity entitlements (the...
2020-10-13 8:00 AM EDT
Portage Announces Reliance on Temporary Regulatory Relief for Filing Q1 Interim Financial Statements
Toronto, Ontario--(Newsfile Corp. - August 28, 2020) - Portage Biotech Inc. (CSE: PBT.U) (OTC Pink: PTGEF) ("Portage" or the "Company") wishes to announce that it will be utilizing the extension period provided under Ontario Instrument 51-505 - Temporary Exemption from Certain Corporate Finance Requirements with Deadlines during the Period from June 2 to August 31, 2020 ("Instrument 51- 505") and similar extension periods provided for by the Canadian Securities Administrators in the other...
2020-08-28 5:45 PM EDT
Portage Announces Filing of Annual Financial Statements
Toronto, Ontario--(Newsfile Corp. - August 24, 2020) - Portage Biotech Inc. (CSE: PBT.U) (OTC Pink: PTGEF) ("Portage" or the "Company") announces that the Company has filed its annual financial statements for the fiscal year ended March 31, 2020, related management's discussion and analysis and officer certifications, as required by Parts 4 and 5 of National Instrument 51-102 ...
2020-08-24 8:00 AM EDT
Portage Announces Reliance on Temporary Regulatory Relief for Filing Annual Financial Statements
Toronto, Ontario--(Newsfile Corp. - July 28, 2020) - Portage Biotech Inc. (CSE: PBT.U) (OTC Pink: PTGEF) ("Portage" or the "Company") announces that it is utilizing the extension period provided under Ontario Instrument 51-505 - Temporary Exemption from Certain Corporate Finance Requirements with Deadlines during the Period from June 2 to August 31, 2020 ("Instrument 51- 505"), and similar extension periods provided for by the Canadian Securities Administrators in the other provinces and...
2020-07-28 8:07 PM EDT